ArticleClinical neuroradiology2025
Hyperdense Middle Cerebral Artery Sign as a Predictor of First-Pass Recanalization and Favorable Outcomes in Direct Thrombectomy Patients.
Article in Clinical neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hyperdense middle cerebral artery sign is not associated with functional outcome following mechanical thrombectomy.Neuroradiology · 2026Article
- Hyperdense middle cerebral artery sign is a prognostic factor of favourable long-term outcomes of mechanical thrombectomy in acute ischaemic stroke.Neuroradiology · 2026Article
- Refractory Thrombectomy: Incidence and Related Factors in a Third-Level Stroke Treatment Center.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe Hyperdense Middle Cerebral Artery Sign (HMCAS) is an early marker of acute MCA occlusion on non-contrast CT (NCCT), which has been linked with stroke type and thrombus composition.
aimsTo assess the prognostic value of HMCAS in M1 occlusion patients treated with endovascular thrombectomy and explore its predictive value across different patients.
methodsPatients with M1 occlusion were selected from the ANGEL-ACT registry, which comprised 1793 individuals. Cohorts were divided based on the presence of HMCAS. The primary outcome was functional independence (mRS 0-2) at 90 days. Secondary outcomes included excellent outcome (mRS 0-1), good functional outcome (mRS 0-3), modified first pass effect (mFPE), successful recanalization, intracranial hemorrhage, and 90-day mortality. Propensity score matching (PSM) was employed to adjust for confounders, with 96 patients in each matched group. Subgroup analysis was performed to determine whether the effect of HMCAS on clinical outcomes differed between groups.
resultsAmong 714 acute M1 occlusion patients, 96 (13.4%) had HMCAS. PSM analysis showed that HMCAS was independently associated with mFPE (OR: 1.97, 95% CI: 1.04-3.75, p = 0.038) but had no significant effects on other clinical outcomes. There was a significant association between HMCAS and functional independence for patients who underwent direct thrombectomy but not for patients who underwent bridging therapy (P for interaction = 0.033).
conclusionThis study indicates that in patients with acute M1 occlusion undergoing EVT, HMCAS on pretreatment NCCT is not significantly associated with functional independence but is linked to a higher first-pass recanalization rate. Its clinical impact on outcomes depends on whether intravenous thrombolysis is administered before thrombectomy.
Indexed as
Identifiers
39704829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.